Suppr超能文献

留置胸腔导管使用的并发症及其处理。

Complications of indwelling pleural catheter use and their management.

机构信息

Division of Respiratory and Critical Care Medicine, Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong; Department of Respiratory Medicine, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia.

Department of Respiratory Medicine, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia; Pleural Medicine Unit, Institute of Respiratory Health, Perth, Western Australia, Australia; Centre for Respiratory Health, School of Medicine & Pharmacology, University of Western Australia, Perth, Western Australia, Australia.

出版信息

BMJ Open Respir Res. 2016 Feb 5;3(1):e000123. doi: 10.1136/bmjresp-2015-000123. eCollection 2016.

Abstract

The growing utilisation of indwelling pleural catheters (IPCs) has put forward a new era in the management of recurrent symptomatic pleural effusions. IPC use is safe compared to talc pleurodesis, though complications can occur. Pleural infection affects <5% of patients, and is usually responsive to antibiotic treatment without requiring catheter removal or surgery. Pleural loculations develop over time, limiting drainage in 10% of patients, which can be improved with intrapleural fibrinolytic therapy. Catheter tract metastasis can occur with most tumours but is more common in mesothelioma. The metastases usually respond to analgaesics and/or external radiotherapy. Long-term intermittent drainage of exudative effusions or chylothorax can potentially lead to loss of nutrients, though no data exist on any clinical impact. Fibrin clots within the catheter lumen can result in blockage. Chest pain following IPC insertion is often mild, and adjustments in analgaesics and drainage practice are usually all that are required. As clinical experience with the use of IPC accumulates, the profile and natural course of complications are increasingly described. We aim to summarise the available literature on IPC-related complications and the evidence to support specific strategies.

摘要

留置性胸腔导管(IPC)的应用日益广泛,为复发性症状性胸腔积液的治疗带来了新的时代。与滑石粉胸膜固定术相比,IPC 的使用更为安全,但也可能出现并发症。胸腔感染影响 <5% 的患者,通常对抗生素治疗有反应,无需拔除导管或手术。随着时间的推移,胸腔分隔会逐渐形成,10%的患者引流受限,可通过胸腔内纤维蛋白溶解治疗来改善。大多数肿瘤都会发生导管窦道转移,但间皮瘤更常见。转移通常对止痛剂和/或外放射治疗有反应。渗出性胸腔积液或乳糜胸的长期间歇性引流可能会导致营养物质流失,但目前尚无任何临床影响的数据。导管腔中的纤维蛋白凝块可能导致阻塞。IPC 插入后胸痛通常较轻,调整止痛剂和引流方案通常就足够了。随着临床应用 IPC 经验的积累,并发症的类型和自然病程越来越多地被描述。我们旨在总结有关 IPC 相关并发症的现有文献,并提供支持特定策略的证据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1e23/4746457/7f6eb2f948bb/bmjresp2015000123f01.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验